ArticleVaccines2022
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease.
Paolo Gisondi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleVaccines2022
Paolo Gisondi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.